<DOC>
	<DOC>NCT00463814</DOC>
	<brief_summary>The primary purpose of the study is to assess the safety, tolerability and pharmacokinetics of a capsule of AZD6244 in patients with advanced solid malignancies.</brief_summary>
	<brief_title>AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>cancer which is refractory to standard therapies WHO performance status 02 evidence of postmenopausal status or negative pregnancy test Radiotherapy/chemotherapy within 21 days prior to entry brain metastases/spinal cord compression unless stable off steroids/anticonvulsants evidence of severe/uncontrolled systemic disease participated in an investigational drug study within 30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Advanced Malignancy</keyword>
	<keyword>Cancer Eligibility</keyword>
	<keyword>Malignancy</keyword>
</DOC>